Eczema is relatively common, affecting 20 percent of children and 10 percent of adults around the world (1). If you are one of the many who experiences eczema, you know the symptoms, which can include ...

Aclaris Therapeutics has secured an exclusive license from Biosion for the global rights to two new antibodies.

About SciBase SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care ...

With the growing prevalence of atopic dermatitis and the increasing demand for innovative treatment options, the market for skin barrier assessment devices is expected to see significant growth in ...

“Lilly Canada stands behind Ebglyss as a first-line biological therapy for the treatment of atopic dermatitis and we remain committed ... via LillyPlus will not change as we tenaciously pursue options ...

Dupilumab (Dupixent), a fully human monoclonal antibody that targets the interleukin (IL)-4 and IL-13 pathways, is currently ...

Enhances Aclaris’ pipeline with complementary biologics portfolio -- Expands leadership team with addition of seasoned ...

Organon is a strong investment opportunity with a high yield, diversified portfolio, steady performance, and transformative ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.

DelveInsight's Dermatological Drugs Market Insights report provides the current and forecast market analysis, individual ...

He is spearheading the Danish Atopic Dermatitis Register for Systemic Treatment (SCRATCH) and providing strategic consultations and advice for the pharmaceutical industry based on his extensive ...

Paris: Sanofi and Regeneron has announced that the US Food and Drug Administration (FDA) has accepted for review the ...